RBN-2397

RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2].

Product Specifications

CAS Number

[2381037-82-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rbn-2397.html

Purity

99.82

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C1C(C(F)(F)F)=C(N[C@@H](C)COCCC(N2CCN(C3=NC=C(C(F)(F)F)C=N3)CC2)=O)C=NN1

Molecular Formula

C20H23F6N7O3

Molecular Weight

523.43

Precautions

H302, H315, H319, H335

References & Citations

[1]RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency|[2]Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.